Levels of cortisol and neurotrophic factor brain-derived in Parkinson’s disease

Costa, Carlos Maurício de Castro; Oliveira, Gabriella Luciana de; Fonseca, Angélica Cristina; Lana, Raquel de Carvalho; Polese, Janaíne Cunha; Pernambuco, Andrei Pereira

doi:10.1016/j.neulet.2019.134359

Cited by 24 publications

(18 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An increase in salivary cortisol levels in PD patients (972.5 pg/mL) compared to HC subjects (425 pg/mL) was reported. Contrarily, no significant difference in plasma BDNF levels of PD patients (215.7 pg/mL) compared to HC subjects (340.1 pg/mL) was observed [54].…”

Section: Salivary Proteins Expressed Differentially: Potential Biomarmentioning

confidence: 77%

“…Additionally, Costa et al evaluated a relationship with the cortisol, the brain-derived neurotrophic factor (BDNF), and PD [54]. Some evidence has shown that in patients with PD, there may be a negative association with BDNF levels, motor deficits, and dopaminergic neuronal loss in the midbrain [55].…”

Section: Salivary Proteins Expressed Differentially: Potential Biomarmentioning

confidence: 99%

See 1 more Smart Citation

Salivary Biomarkers: Future Approaches for Early Diagnosis of Neurodegenerative Diseases

et al. 2020

View full text Add to dashboard Cite

Many neurological diseases are characterized by progressive neuronal degeneration. Early diagnosis and new markers are necessary for prompt therapeutic intervention. Several studies have aimed to identify biomarkers in different biological liquids. Furthermore, it is being considered whether saliva could be a potential biological sample for the investigation of neurodegenerative diseases. This work aims to provide an overview of the literature concerning biomarkers identified in saliva for the diagnosis of neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). Specifically, the studies have revealed that is possible to quantify beta-amyloid1–42 and TAU protein from the saliva of AD patients. Instead, alpha-synuclein and protein deglycase (DJ-1) have been identified as new potential salivary biomarkers for the diagnosis of PD. Nevertheless, future studies will be needed to validate these salivary biomarkers in the diagnosis of neurological diseases.

show abstract

Section: Salivary Proteins Expressed Differentially: Potential Biomarmentioning

confidence: 77%

Section: Salivary Proteins Expressed Differentially: Potential Biomarmentioning

confidence: 99%

Salivary Biomarkers: Future Approaches for Early Diagnosis of Neurodegenerative Diseases

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Moreover, MAO-B inhibitors, (-) deprenyl and rasagiline, increased neurotrophic factor levels in the cerebrospinal fluid of patients with PD (Naoi and Maruyama 2009 ). A negative association was found between BDNF plasma levels and severity of anxiety and depression (HAM-A and HAM-D scores) (Costa et al 2019 ; Yang et al 2020 ).…”

Section: Depressionmentioning

confidence: 99%

Recent advances in the pathology of prodromal non-motor symptoms olfactory deficit and depression in Parkinson’s disease: clues to early diagnosis and effective treatment

2021

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a progressive neurodegenerative disease characterized by movement dysfunction due to selective degeneration of dopaminergic neurons in the substantia nigra pars compacta. Non-motor symptoms of PD (e.g., sensory dysfunction, sleep disturbance, constipation, neuropsychiatric symptoms) precede motor symptoms, appear at all stages, and impact the quality of life, but they frequently go unrecognized and remain untreated. Even when identified, traditional dopamine replacement therapies have little effect. We discuss here the pathology of two PD-associated non-motor symptoms: olfactory dysfunction and depression. Olfactory dysfunction is one of the earliest non-motor symptoms in PD and predates the onset of motor symptoms. It is accompanied by early deposition of Lewy pathology and neurotransmitter alterations. Because of the correlation between olfactory dysfunction and an increased risk of progression to PD, olfactory testing can potentially be a specific diagnostic marker of PD in the prodromal stage. Depression is a prevalent PD-associated symptom and is often associated with reduced quality of life. Although the pathophysiology of depression in PD is unclear, studies suggest a causal relationship with abnormal neurotransmission and abnormal adult neurogenesis. Here, we summarize recent progress in the pathology of the non-motor symptoms of PD, aiming to provide better guidance for its effective management.

show abstract

“…Based on sample size estimations, 29 participants were required per group (α = 0.05, 1 − β = 0.8) 28 . However, as this study was ancillary to another study, recruitment was limited to the participant pool of the parent study, as well as other factors such as hair length, pigment loss and hair dying.…”

Section: Discussionmentioning

confidence: 99%

Hair and salivary cortisol and their relationship with lifestyle, mood and cognitive outcomes in premanifest Huntington’s disease

Cruickshank

Porter

Laws

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Salivary cortisol dysrhythmias have been reported in some, but not all studies assessing hypothalamic–pituitary–adrenal (HPA) axis function in Huntington’s disease (HD). These differences are presumed to be due to environmental influences on temporal salivary cortisol measurement. Further exploration of HPA-axis function using a more stable and longer-term measure, such as hair cortisol, is needed to confirm earlier findings. This study aimed to evaluate hair and salivary cortisol concentrations and their associations with clinical and lifestyle outcomes in individuals with premanifest HD (n = 26) compared to healthy controls (n = 14). Participants provided saliva and hair samples and data were collected on clinical disease outcomes, mood, cognition, physical activity, cognitive reserve, sleep quality and social network size to investigate relationships between clinical and lifestyle outcomes and cortisol concentrations. Hair and salivary cortisol concentrations did not significantly differ between the premanifest HD and control groups. No significant associations were observed between hair or salivary cortisol concentrations and cognitive, mood or lifestyle outcomes. However, hair cortisol concentrations were significantly associated with disease outcomes in individuals with premanifest HD. Significant associations between hair cortisol concentrations and measures of disease burden and onset may suggest a potential disease marker and should be explored longitudinally in a larger sample of individuals with HD.

show abstract

Levels of cortisol and neurotrophic factor brain-derived in Parkinson’s disease

Cited by 24 publications

References 33 publications

Salivary Biomarkers: Future Approaches for Early Diagnosis of Neurodegenerative Diseases

Salivary Biomarkers: Future Approaches for Early Diagnosis of Neurodegenerative Diseases

Recent advances in the pathology of prodromal non-motor symptoms olfactory deficit and depression in Parkinson’s disease: clues to early diagnosis and effective treatment

Hair and salivary cortisol and their relationship with lifestyle, mood and cognitive outcomes in premanifest Huntington’s disease

Contact Info

Product

Resources

About